PMID- 34003475
OWN - NLM
STAT- MEDLINE
DCOM- 20220118
LR  - 20220218
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Print)
IS  - 1734-1140 (Linking)
VI  - 73
IP  - 4
DP  - 2021 Aug
TI  - Insights into a possible role of glucagon-like peptide-1 receptor agonists in the 
      treatment of depression.
PG  - 1020-1032
LID - 10.1007/s43440-021-00274-8 [doi]
AB  - Depression is a highly prevalent mood disorder and one of the major health 
      concerns in modern society. Moreover, it is characterized by a high prevalence of 
      coexistence with many other diseases including metabolic disorders such as type 2 
      diabetes mellitus (T2DM) and obesity. Currently used antidepressant drugs, which 
      mostly target brain monoaminergic neurotransmission, have limited clinical 
      efficacy. Although the etiology of depression has not been fully elucidated, 
      current scientific data emphasize the role of neurotrophic factors deficiencies, 
      disturbed homeostasis between the nervous system and the immune and endocrine 
      systems, as well as disturbances in brain energy metabolism and dysfunctions in 
      the gut-brain axis as important factors in the pathogenesis of this 
      neuropsychiatric disorder. Therefore, therapeutic options that could work in a 
      way other than classic antidepressants are being sought to increase the 
      effectiveness of the treatment. Interestingly, glucagon-like peptide-1 receptor 
      agonists (GLP-1RAs), used in the treatment of T2DM and obesity, are known to show 
      pro-cognitive and neuroprotective properties, and exert modulatory effects on 
      immune, endocrine and metabolic processes in the central nervous system. This 
      review article discusses the potential antidepressant effects of GLP-1RAs, 
      especially in the context of their action on the processes related to 
      neuroprotection, inflammation, stress response, energy metabolism, gut-brain 
      crosstalk and the stability of the gut microbiota.
CI  - (c) 2021. The Author(s).
FAU - Detka, Jan
AU  - Detka J
AUID- ORCID: 0000-0002-9866-5777
AD  - Laboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, 
      Polish Academy of Sciences, Maj Institute of Pharmacology, 12 Smetna Street, 
      31-343, Cracow, Poland. detka@if-pan.krakow.pl.
FAU - Glombik, Katarzyna
AU  - Glombik K
AD  - Laboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, 
      Polish Academy of Sciences, Maj Institute of Pharmacology, 12 Smetna Street, 
      31-343, Cracow, Poland.
LA  - eng
GR  - Statutory Funds/Instytut Farmakologii, Polskiej Akademii Nauk/
PT  - Journal Article
PT  - Review
DEP - 20210518
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Antidepressive Agents)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/*pharmacology
MH  - Depression/*drug therapy/metabolism
MH  - Energy Metabolism/drug effects
MH  - Gastrointestinal Microbiome/drug effects
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Humans
MH  - Inflammation/drug therapy/metabolism
MH  - Neuroprotection/drug effects
PMC - PMC8413152
OTO - NOTNLM
OT  - Depression
OT  - Exendin-4
OT  - GLP-1
OT  - Gut-brain axis
OT  - HPA axis
OT  - Liraglutide
COIS- The authors declare no conflict of interests.
EDAT- 2021/05/19 06:00
MHDA- 2022/01/19 06:00
PMCR- 2021/05/18
CRDT- 2021/05/18 12:26
PHST- 2021/01/31 00:00 [received]
PHST- 2021/05/06 00:00 [accepted]
PHST- 2021/05/04 00:00 [revised]
PHST- 2021/05/19 06:00 [pubmed]
PHST- 2022/01/19 06:00 [medline]
PHST- 2021/05/18 12:26 [entrez]
PHST- 2021/05/18 00:00 [pmc-release]
AID - 10.1007/s43440-021-00274-8 [pii]
AID - 274 [pii]
AID - 10.1007/s43440-021-00274-8 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2021 Aug;73(4):1020-1032. doi: 10.1007/s43440-021-00274-8. Epub 
      2021 May 18.